THE IMPORTANCE OF VANILLYLMANDELIC ACID DETERMINATION IN OPIATE USERS



Similar documents
Naltrexone Pellet Treatment for Opiate, Heroin, and Alcohol Addiction. Frequently Asked Questions

1. According to recent US national estimates, which of the following substances is associated

Office-based Treatment of Opioid Dependence with Buprenorphine

Care Management Council submission date: August Contact Information

DSM-IV Alcohol Dependence. Alcohol and Drug Abuse. Screening for Alcohol Risk. DSM-IV Alcohol Abuse

Considerations in Medication Assisted Treatment of Opiate Dependence. Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT

Tolerance and Dependence

Frequently asked questions

Using Drugs to Treat Drug Addiction How it works and why it makes sense

One example: Chapman and Huygens, 1988, British Journal of Addiction

Neurobiology and Treatment of Opioid Dependence. Nebraska MAT Training September 29, 2011

8/1/2014. Who We Are. BHG s Medical Mission. BHG Company Overview

Substitution Therapy for Opioid Dependence The Role of Suboxone. Mandy Manak, MD, ABAM, CCSAM Methadone 101-Hospitalist Workshop, October 3, 2015

OVERVIEW OF MEDICATION ASSISTED TREATMENT

The CCB Science 2 Service Distance Learning Program

Causes of Alcohol Abuse and Alcoholism: Biological/Biochemical Perspectives

William Shaw, Ph.D. The Great Plains Laboratory, Inc., Lenexa, Kansas, USA

Heroin. How is Heroin Abused? What Other Adverse Effects Does Heroin Have on Health? How Does Heroin Affect the Brain?

Heroin. How Is Heroin Abused? How Does Heroin Affect the Brain? What Other Adverse Effects Does Heroin Have on Health?

New York State Office of Alcoholism & Substance Abuse Services Addiction Services for Prevention, Treatment, Recovery

Treatment of opioid use disorders

ADVANCED BEHAVIORAL HEALTH, INC. Clinical Level of Care Guidelines

Heroin. How Is Heroin Abused? How Does Heroin Affect the Brain? What Other Adverse Effects Does Heroin Have on Health?

Dependence and Addiction. Marek C. Chawarski, Ph.D. Yale University David Metzger, Ph.D. University of Pennsylvania

Understanding Addiction: The Intersection of Biology and Psychology

TENNESSEE BOARD OF MEDICAL EXAMINERS POLICY STATEMENT OFFICE-BASED TREATMENT OF OPIOID ADDICTION

Prior Authorization Guideline

MEDICAL ASSISTANCE BULLETIN

Alcohol Overuse and Abuse

In 2010, approximately 8 million Americans 18 years and older were dependent on alcohol.

Minimum Insurance Benefits for Patients with Opioid Use Disorder The Opioid Use Disorder Epidemic: The Evidence for Opioid Treatment:

Treatment of Opioid Dependence with Buprenorphine/Naloxone (Suboxone )

DRUG AND ALCOHOL DETOXIFICATION: A GUIDE TO OUR SERVICES

Buprenorphine: what is it & why use it?

EPIDEMIC 4.6 % OF INDIVIDUALS USED PAIN RELIEVERS FOR NON-MEDICAL REASONS. 1.5 MILLION YOUNG ADULTS USED PAIN RELIEVERS IN THE PAST MONTH.

Alcohol Withdrawal Syndrome & CIWA Assessment

We re glad you are here! Agenda for the Day Breaks Lunch Q&A and note cards Phones

Treatment of Opioid Dependence: A Randomized Controlled Trial. Karen L. Sees, DO, Kevin L. Delucchi, PhD, Carmen Masson, PhD, Amy

Death in the Suburbs: How Prescription Painkillers and Heroin Have Changed Treatment and Recovery

DEVELOPING MANUFACTURING SUPPLYING. Naltrexone Implants. Manufactured by NalPharm Ltd

Psychiatric Comorbidity in Methamphetamine-Dependent Patients

Information for Pharmacists

Alcohol and Drug. A Cochrane Handbook. losief Abraha MD. Cristina Cusi MD. Regional Health Perugia

Opioid Agonist Therapy: The Duration Dilemma Edwin A. Salsitz, MD, FASAM Mount Sinai Beth Israel, New York, NY March 10, 2015

Use of Buprenorphine in the Treatment of Opioid Addiction

Alcohol Withdrawal. Introduction. Blood Alcohol Concentration. DSM-IV Criteria/Alcohol Abuse. Pharmacologic Effects of Alcohol

Beroendemekanismer- ett beroende som andra?

Prior Authorization Guideline

Introduction to Tolerance, Physical Dependence and Withdrawal

Developing Medications to Treat Addiction: Implications for Policy and Practice. Nora D. Volkow, M.D. Director National Institute on Drug Abuse

Naloxone treatment of opioid overdose

Behavioral Health Policy: Methadone Treatment and Intensive Detoxification or Ultra-Rapid Detoxification for Opiate Addiction

Medications Used in the Treatment of Addiction Developed by Randall Webber, MPH. Alcohol Withdrawal

Alcohol and Prescription opiate abuse: Responsibilities of Stakeholders to reduce the problem. Thomas Kosten MD

Pain, Addiction & Methadone

opiates alcohol 27 opiates and alcohol 30 April 2016 drug addiction signs 42 Ranked #1 123 Drug Rehab Centers in New Jersey 100 Top

EPIDEMIOLOGY OF OPIATE USE

Discontinuation: Involuntary Discharge

MEDICAL ASSISTANCE BULLETIN

MEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION

The NJSAMS Report. Heroin Admissions to Substance Abuse Treatment in New Jersey. In Brief. New Jersey Substance Abuse Monitoring System.

Hospital Management of Opioid Dependence. Dependence. Disclosure. Pharmacologic Management. Methadone Utilization. Hospital Management of Opioid

Dosing Guide. For Optimal Management of Opioid Dependence

OTC Abuse. Dr. Eman Said Abd-Elkhalek Lecturer of Pharmacology & Toxicology Faculty of Pharmacy Mansoura University

The Federation of State Medical Boards 2013 Model Guidelines for Opioid Addiction Treatment in the Medical Office

HAWAII BOARD OF MEDICAL EXAMINERS PAIN MANAGEMENT GUIDELINES

Opioid/Opiate Dependent Pregnant Women

Update on Buprenorphine: Induction and Ongoing Care

Source: National Institute on Alcohol Abuse and Alcoholism. Bethesda, Md: NIAAA; NIH Publication No

Putting Addiction Treatment Medications to Use: Lessons Learned

OPIOIDS. Petros Levounis, MD, MA Chair Department of Psychiatry Rutgers New Jersey Medical School

Drugs, The Brain, and Behavior

a. positive vs. negative reinforcement b. tolerance vs. sensitization c. drug classes einforcement

Brain Damage & Recovery: The Resilience of the Brain, Addiction Impact & Therapeutic Repair. Michael Fishman, MD Director of Young Adult Program

The opioids and heroin. Dr Deny Susanti

The latest in addiction medicine: What every nurse needs to know

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Source: National Institute on Alcohol Abuse and Alcoholism. Bethesda, Md: NIAAA; NIH Publication No

fmri studies of addiction and relapse Rebecca Elliott Bill Deakin Anna Murphy Neuroscience and Psychiatry Unit

METHADONE SUBSTITUTION THERAPY PROGRAM AND TOXICOLOGICAL STUDIES

Treatment of Prescription Opioid Dependence

MAT Counselor Education Course Exam Questions Packet Part 1

ST. CLAIR COUNTY COMMUNITY MENTAL HEALTH Date Issued: 07/09 Date Revised: 09/11;03/13;06/14;07/15

Program Assistance Letter

Treating Addiction in Chronic Pain Patients A Clinical Journey. Brad Anderson, MD Chief, Department of Addiction Medicine Kaiser Permanente Northwest

Adjunctive psychosocial intervention. Conditions requiring dose reduction. Immediate, peak plasma concentration is reached within 1 hour.

Update and Review of Medication Assisted Treatments

Triage, Assessment & Treatment

SUBOXONE for Opioid Addiction Medication Assisted Therapy. Dr. Jennifer Melamed MBChB, ABAM, CISAM, CCSAM

Table of Contents. I. Introduction II. Summary A. Total Drug Intoxication Deaths B. Opioid-Related Deaths... 9

Opioids Research to Practice

Medication Assisted Treatment. Ned Presnall, MSW, LCSW May 17, 2014

SCOTTISH PRISON SERVICE DRUG MISUSE AND DEPENDENCE OPERATIONAL GUIDANCE

Today s Topics. Session 2: Introduction to Drug Treatment. Treatment matching. Guidelines: where should a client go for treatment?

Transcription:

JMB 2009; 28 (3) DOI: 10.2478/v10011-009-0015-x UDK 577.1 : 61 ISSN 1452-8258 JMB 28: 197 201, 2009 Original paper Originalni nau~ni rad THE IMPORTANCE OF VANILLYLMANDELIC ACID DETERMINATION IN OPIATE USERS VA@NOST ODRE\IVANJA KONCENTRACIJE VANILMANDELI^NE KISELINE KOD LJUDI KOJI KORISTE OPIJATE Danijela Jani}evi}-Ivanovska 1, Aneta Spasovska-Trajkovska 2, Branko Stefanovski 2, Slavica Subeska-Stratrova 3, Jasmina Mecevska Jovcevska 1 1University Clinic for Clinical Biochemistry 2University Clinic for Psychiatry 3University Clinic for Endocrinology, University Clinical Center, Skopje, R. Macedonia Summary: Although knowledge about the etiology of heroin dependence is rather poor, it is known that the influ - ence of opiates on the opioid, adrenergic and indirectly of GABA on the dopaminergic receptors leads to changes of catecholamine levels in brain structures, which are supposed to be essential in explaining the etiology of the opioid de pen - dence. It is well-known that by analyzing catecholamine, we get vanillylmandelic acid (VMA), which is found in the urine as a final product. Thus, by an indirect determination of VMA it is also possible to define the catecholamine concen - tration in the brain, which is the aim of this study. This prospective study included 51 dependent heroin users divi - ded into 3 groups, depending on the length of the medical treatment with a conventional detox method (without treat - ment, second day of the treatment, and after the 10th day of treatment) as well as a control group consisting of 20 healthy subjects. We used the Pissano method chr o mato - graphic-spectrophotometric determination for estimating the level of vanillylmandelic acid, and a scale for de fining the severity of symptoms of the withdrawal syndrome (WS). The results showed that the highest average values of the urinary level of VMA were found in the subjects in withdrawal crisis with a high WS scale score in com parison with the other examined groups (statistically signi ficant) as a result of the high adrenergic level. The average score on the scale of depression was high in the subjects in withdrawal crisis where we also found low values of the VMA urinary level. Being aware of the neurobiology of heroin dependence is of great importance for finding new pharmacological treat ments for heroin addiction. Keywords: vanillylmandelic acid, opioid addiction, withdrawal syndrome Kratak sadr`aj: Siroma{na su saznanja o etiologii opioidne zavisnosti, ali se ipak smatra da opijati deluju na opioidne adrenergi~ne i po indirektnom putu preko GABA na dopaminske receptore, dovode}i do promene kateho - lamin skih nivoa u mo`danim strukturama, za koje se pretpo stavlja da su va`ne za obja{njenje etiologije opioidne zavis nosti. Poznato je da se razgradnjom kateholamina dobija vanilmandeli~na kiselina (VMA), kao poslednji produkt u urinu, pa postoji mogu}nost da se odre ivanjem njene kon cen tracije indirektnim putem proceni i koncen - tracija kate holamina u mozgu, {to je i cilj ovog rada. Pro - spek tivna studija obuhvata ukupno 51 heroinskih zavisnika na detoksikacionom programu, podeljenih u tri grupe u zavis nosti od medicinskog tretmana prva grupa su he - roinski zavisnici (bez tretmana), druga grupa zavisnici koji su zapo~eli tretman dva dana ranije, tre}a grupa heroinski zavisnici koji su pre 10 dana po~eli tretman (stabilizanti), i kontrolna grupa od 20 zdravih ispitanika. Tokom istra `i - vanja kori{}en je metod Pissano hromato grafsko spektro - fo tometrijsko odre ivanje nivoa VMA, i skala za procenu ja~ine simptoma apstinencijalne krize (WS). Dobijeni re - zultati uka zuju da najve}e prose~ne vrednosti urinarnih nivoa VMA imaju heroinski zavisnici koji su u apstinen ci - jalnoj krizi gde se vidi i visoki skor WS skale u odnosu na druge grupe, kao rezultat visokog adrener gi~nog nivoa. Prose~ni skor skale depresivnosti je visok kod zavisnika (10 dana od po~etka tretmana gde postoji nizak nivo VMA). Poznavanje neu ro bio logije opioidnih zavisnika, od veli kog je zna~aja za pro nala`enje novih farmakolo{kih tretmana za njihovo le~enje. Klju~ne re~i: vanilmandeli~na kiselina, opioidna za vi - snost, apstinencijalni sindrom Address for correspondence: Danijela Jani}evi}-Ivanovska University Clinic for Clinical Biochemistry University Clinical Center, Skopje, R. Macedonia Mobil: +389 70 678 727 e-mail: djanicevicªyahoo.com

198 Jani}evi}-Ivanovska et al.: Vanillylmandelic acid in opiate users Introduction The term opiates is used for psychoactive sub - stances as well as for the half-synthetic drug heroin, which is produced from poppy seeds. Intake of heroin into the human organism via nasal snorting, by inhaling its vapors, that is, heating heroin on a piece of foil, and intravenous injection have influence on the intensity and character of the negative effects (1). High liposolubility of heroin enables rapid heroin cros sing of the blood-brain barrier and the conse - quent meta bolic activation of CNS. Heroin is hydro - lyzed to 9-monoacetylmorphine that enters the CNS and has the same pharmacological characteristics as heroin. It is further deacylated to morphine, which remains present and potent in the CNS long after heroin elimination from the organism (2). Opioid dependence is a result of the effect of opioid adrenergic receptors and indirectly of GABA effect on dopamine receptors that lead to changes of catecholamine levels in the brain structures, which indirectly assess the heroin effects on the CNS (3, 4). It is also assumed that the dosage is not the unique factor for the changes in the organism that appear after heroin use, but the mode of application is essential, too (high doses by intravenous injection lead to fatal outcome) (5). All these are important for further therapeutic procedures (6). The dose and time duration of opiate appli ca - tion are in positive correlation with the clinical picture of opiate dependence along with the catecholamine levels in the brain that are indirectly precisely assessed through their urine catecholamine products va nillyl - mandelic acid (VMA). By catecholamine degradation under the effect of the enzyme catecholamine-omethyl-transferase (COMT) VMA is obtained, which is found in the urine as a final product (7). VMA values reflect the real catecholamine pro - duction in the brain structures. Thus, determination of VMA in urine is very important in order to assess the indirect heroin effect on catecholamine pro duc tion in the brain (8 10). Some studies have re ported that by the effect of heroin on brain struc tures, changes in the level of catecholamine, that is, catecholamine con - centration in the organism are also provoked. Heroin arouses pleasant feelings, but on the other hand, with - drawal crisis may appear as well as the addiction syndrome (11). In this paper, the presence of VMA that is found as a final product in the urine of opioid-dependent drug users was determined, as well as the indirect VMA influence on CNS during a ten-day period in undergoing a detoxification program. Material and Methods The investigation included 51 subjects of both sexes, aged between 18 and 35 years (mean age 22 years), who signed a written consent for their partici - pation in this investigation. The were divided into three groups depending on the duration of detoxification treatment. Detoxification was done with benzodiazepines and parenterally with vitamins from the B-complex group. Sixteen (22%) who are regular users of opiate agents (heroin) without treatment (first day of heroin interruption) were named group A; 18 (35.4 %) who were undergoing detoxification treatment on day 2 (second day after heroin inter - ruption, when withdrawal crisis appears) were named group B; 17 (23.9%) who were under going detoxification treatment on day 10 (tenth day after heroin interruption and they were in a stable condition) were named group C. The control group consisted of 20 healthy subjects blood donors, with normal laboratory findings, with similar distribution by sex and age as the examined. This group was named H. VMA was determined in all subjects. 24-hour urine was collected and acidified with 10 ml HCl. VMA was determined using the Pissano method chromatographic-spectrophotometric determination (12). VMA reference values are 9.0 34.6 mmol/24h. The results obtained were statistically analyzed with the SPSS 10 for Windows statistical program. A method for descriptive statistical analyses, Stu dent s t- test was used for the analysis. Values of p<0.005 were considered to be statistically significant. Results By applying the t-test for independent samples we tested the differences in the average length of heroin dependence between the three examined groups. Subjects from group B had significantly longer opioid addiction in comparison with group A (p<0.05); significantly longer in comparison with those in the stabilization phase, group C (p<0.001), while the length of opioid addiction in group A was insignifi cantly longer in subjects on street heroin (group A) than in subjects who were in the detoxification pro gram for 10 days, group C (p>0.05). The highest average VMA values were found in group B (50.9 ± 8.7), lower in group A (38.8 ± 9.2), the lowest in group C (33.2 ± 6.1), and in the control group H (32.3 ± 1.2). Table I Mean values of VMA urinary level by groups. VMA, mmol/l N Mean Min Max SD Group B 18 50.95h 37.60 62.70 8.66 Group A 16 38.85h 27.30 62.50 9.19 Group C 17 33.22 22.10 43.20 6.08 Control group H 20 32.34 30.00 34.00 1.18

JMB 2009; 28 (3) 199 Table II Distribution of values of the severity of withdrawal symptoms (WS) by groups. WS Group B Group A Group C 1 moderate 0 0 12 75.00 17 100.00 2 mild 8 44.44 4 25.00 0 0 3 severe 10 55.56 0 0 0 0 Total number of 18 100.00 16 100.00 17 100.00 Group B had significantly higher average values of VMA (50.09 ± 8.7) in comparison with the control group (32.3 ± 1.2) (p<0.001). Group A had also significantly higher values (38.8 ± 9.2) (p<0.001), whereas the VMA value in group C (33.2 ± 6.1) did not significantly differ in comparison to the control group H. Deviations from the normal values ( 34 μmol/l) with regard to increased average values were regi - stered in the addicts from group B and group A. The results of the tested differences of average VMA serum concentrations between the examined groups are presented in Table I. The subjects from group B had significantly higher average values of the analyzed acid in comparison with the other examined groups (p<0.01). Heroin addicts from group A had signi - ficantly higher average values of VMA in comparison with both addicts from group C (p<0.05) and control subjects (p<0.01). Withdrawal crisis according to the withdrawal scale scores can be mild, moderate and severe. Among addicts in the acute phase (group B), there were no subjects with moderate form of withdrawal crisis, while more than 50% of these subjects had severe degrees of withdrawal crisis. Among street heroin-dependent users (group A), there were none with a severe degree of withdrawal crisis, 75% had a moderate degree and 25% a mild degree that was the result of abstinence. All 17 in the stabilization phase (group C) had a moderate degree of with dra - wal crisis. Obtained results are shown in Table II. Discussion Some studies have reported increased urinary elimination of the catecholamine metabolite 3- -methoxy-4-hydroxyphenylglycol (MHPG) in the majority of heroin addicts in comparison with a control group (13). In the study conducted by Roffman et al. (14), the level of catecholamines, that is, their urinary metabolite VMA was monitored and it was proved that VMA increase was analogous to heroin admini stration in the group of examined drug users (chronic heroin addicts) and it was bigger in com parison with the control group. Also, the investigation conducted by Macedo et al. (15) showed that the plasma level of conjugated catecholamine was increased in heroin addicts. In our study we examined the urinary level of VMA and the results obtained showed that street heroin-drug users from group A had significantly higher average VMA values than the control group of subjects. Literature data have confirmed a positive relation between the length of opioid addiction and changes in the catecholamine level during opiate abuse (16). There is a positive correlation between VMA concentrations in urine and the length of opioid addic tion. The value of coefficient P has shown that the relation ranges between moderate and high in addicts in severe withdrawal crisis. Concentration of vanillyl mandelic acid in urine increases proportionally with the length of opioid addiction; long-term addiction is associated with higher concentrations of this acid. The from group B who were in the second day of the detoxification program were found to be in a more severe withdrawal crisis and they were longer-term addicts. This relation, that is correlation, is strong and is statistically significant. During early withdrawal crisis an increase in catecholamine secretion was noticed monitored by increase of the excretion of urinary MHPG and VMA (17). We have also examined the urinary level of VMA and the results obtained pointed to significantly highest average values of VMA in comparison with the remaining groups and the control group. The subjects in acute withdrawal crisis had significantly higher average values of the analyzed acid when compared to the other groups. According to some researchers the urinary level of VMA in the first days of withdrawal crisis in opioid addicts is increased and then stabilized to the normal level (18). Results presented in the study of Alec Roy demonstrated that there were no significant differen - ces of correlation between the plasma level of VMA in

200 Jani}evi}-Ivanovska et al.: Vanillylmandelic acid in opiate users abstinent heroin dependent addicts when compared with the control group and in relation to the number of days of abstinence (until the 28 th day of abstinence and after the 28 th day of abstinence) (19). In our subjects from the group of stable exami - nees (abstinent after the 10th day of deto - xification), a significant decrease of the urinary level of VMA was proved in comparison with the other groups and the control group (healthy population). The obtained average values of VMA in addicts in the stabilization phase did not differ significantly from those in the healthy subjects, that is, the tested differences between them were statistically insigni - ficant. In the programs for detoxification with pheno - thiazines and benzodiazepines the most commonly used protocol for detoxification treatment is based on the grounds that in opioid addiction there is presy nap - tic dopaminergic stimulation, and thus the most frequently applied medications are those that block the dopamine release dopamine antagonists (20, 21). According to some studies the severity of with - drawal crisis is in direct correlation with the applied dose, intravenous injection and length of opiod addiction (22). The in their second day of the detoxification program experience a more severe withdrawal crisis if they are long-term addicts. Usually, long-term heroin use is related to increase of the dose, which leads to emphasizing the withdrawal signs and symptoms (as was the case with the group B in our study). Opioid-dependent addicts from the group A had increased values when compared with the controls. The VMA values in the subjects from the group C did not significantly differ from group H, which points to the fact that these values are a result of successful detoxification and can be used as a predictor for further successful treatment. Testing differences of the withdrawal scale sco res in all examined relations were highly statistically significant (p<0.01). Therefore, a conclusion could be drawn that subjects in the acute withdrawal crisis have significantly higher scores on the withdrawal scale than the on the first day and those in the stabilization phase the 10th day of treatment (23, 24). Also, on their first day of treatment had significantly higher scale scores than those in the stabilization phase (the 10 th day of treatment); how - ever, this statistical significance was smaller than the significance registered between the in acute state and the remaining two groups. The results of this clinical study have confirmed the expected conclusions, having in mind the numerous cited references. In conclusion, opioid addiction is characterized by an increased VMA value in the urine, especially in the withdrawal crisis that is characterized by signifi - cantly high VMA values and is of key importance for the assessment of the severity of withdrawal crisis. The detoxification program conducted on heroindepen dent addicts enables normalization of the VMA values on the 10th day of treatment. Our notions imply that VMA determination is indispensable for the indirect assessment of opioid addiction and for the course and outcome of the treatment. This means that opioid addiction as a diagnosis should be taken into account serio usly and adequately treated for the well-being of opioid-dependent drug users. References 1. Zquierdo Patron M, Martinez-Moratalla J, Gonzales Valladers G. Broncho-spasm from heroin inhalation. An Med Interna 2001; 18: 165. 2. McFarland K, Ettenberg A. Haloperidol does not atte - nuate conditioned place preferences or locomotors activa tion produced by food or heroin-predictive discriminative cues. Pharmacology, biochemistry, and behavior 1999; 62: 631 41. 3. Lawford B, Young R, Noble E, Sargent J, Rowel J. The D2 Dopamine Receptor A1 Allele and Opioid Depen - dence: Association With Heroin Use and Response to Methadone Treatment. American Journal of Medical Genetics Neuropsychiatric Genetics 2000; 96: 592 8. 4. Cousins MS, Roberts DC, De Wit H. GABA (B) receptor agonists for the treatment of drug addiction: a review of recent findings. Drug and alcohol dependence 2002; 65: 209 20. 5. Platt DM, Rowlett JP, Spealman RD. Discriminative, stimulus effects of intravenous heroin and its metabo - lites in rhesus monkeys: opioid and dopaminergic mechanisms. Journal of pharmacology and experimen - tal therapeutics 2001; 299: 760 7. 6. Giannini J. An Approach to Drug Abuse. Intoxication and Withdrawal. Am Fam Psych 2000; 661: 2763 74. 7. Cadlovski G. Nevroleptici. Koniks 1999; 12 50, 86 92. 8. De Maio D, Caponeri MA, Cicchetti V, Mellado C, Scieghgi G. Sulpiride and extrapyramidal syndromes in chronic heroin addiction. Neuropsychobiology 1978; 4: 36 9. 9. Gerra G, Zaimovic A, Zambelli U, Delsignore R, Baroni MC, Laviola G. Neuroendocrine correlates of depres - sion in abstinent heroin-dependent subjects. Psychiatry research 2000; 96: 221 34. 10. The effects of heroin on catecholamine metabolism in man. Natl Inst Drug Abuse Res Monogr Ser. 1985; 137 45.

JMB 2009; 28 (3) 201 11. EMCDDA. Evaluating the treatment of Drug Abuse in the European Union. Luxemburg: Office for Official Publications of the European Communities, 1999: 13 28. 12. Pissano J, Crout R, Abraham D. Determination of 3- -methoxy-4-hydroxymandelic acid in urine. Clin Chim Acta 1962; 7: 277 84. 13. Schildkraut J, Meyer RE, Orsulak PJ, Mirin SM, Roffman M, Platz PA, Grab E, Randall ME, McDougle M. Cate - chol amine metabolism during heroin use. Am J Psychiatry 1997; 134: 534 7. 14. Roffman M, Platz PA, Grab E, et al. The effects of heroin on catecholamine metabolism in man. Nat Inst Drug Abuse 1995 (3): 137 45. 15. Macedo TR, Riberio A, Morgandino T, et al. Influence of concurrent heroin and cocain abuse on the adre - nergic and seratonergic system in man. Annals of the New York Academy of Sciences 1998; 844: 208 13. 16. Kish SJ, Kalasinky KS, Derkach P, et al. Striatal dopa - minergic and serotonergic markers in human heroin users. Neuropsychopharmacology: official publi cation of the American College of Neuropsycho phar macology 2001; 24 (5): 561 7. 17. Hunyor S, Hansson L, Harrison T, Hoobler S. Effects of Clonidine Withdrawal: Possible Mechanisms and Sugges tions for Management. Br Med J 1973; 28: 2 (5860): 209 11. 18. Warner-Smith M, Darke S, Lynskey M, Hall W. Heroin overdose: causes and consequences. Addiction 2001; 96; 11: 3 25. 19. Roy A, Berman J, Williams R, Kuhn C, Gonzalez B. Higher Levels of CSF Homovanillic Acid in Recently Abstinent Cocaine-Dependent Patients. Am J Psychiatry 2002, 159: 1053 5. 20. Collier H, Francis D, Roy A. Opiates, cyclic nucleotides, and xanthenes. Advances in biochemical psychophar - macology 1976; 15: 337 45. 21. De Vries TJ, Schoffelmeer AN, Binnekade R, Raaso H, Vanderschuren LJ. Relapse to cocaine- and heroinseeking behavior mediated by dopamine D2 receptors is time-dependent and associated with behavioral sensitization. Neuropsychopharmacology 2002; 26: 18 26. 22. EMCDDA. Extended annual report on the state of the drugs problem in the European Union 1999. Luxem - burg: Office for Official Publications of the European Communities, 1999: 9. 23. Oliveira MT, Rego AC, Morgadinho MT, Macedo TR, Oliveira CR. Toxic effects of opioid and stimulant drugs on undifferentiated PC 12 Cells. Annals of the New York Academy of Sciences 2002; 965: 487 96. 24. Ghaffari-Nejad A, Sabih K. The relationship between heroin withdrawal signs and symptoms and existence of depression. Arch Iranian Med 2005; 8: 115 8. Received: January 10, 2009 Accepted: April 11, 2009